Browse studies

Find your next paid study

1 recruiting study matching your filters

A Phase 1, Multicenter, Open-Label Study of REM-422, an MYB mRNA Degrader, in Patients With Relapsed/Refractory AML or Higher-Risk MDS

The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with Higher Risk MDS and relapsed/refractory…

Myelodysplastic SyndromesHigher Risk Myelodysplastic SyndromesAcute Myeloid Leukemia+1 more

Remix TherapeuticsNCT06297941